Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 5:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 372 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Recurrent Rectal Carcinoma Clear all
Completed No phase listed Observational
View directory record Official record
Conditions
Cancer
Interventions
protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy
Genetic · Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 120 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Colorectal Cancer
Interventions
fluorouracil, leucovorin calcium
Drug
Lead sponsor
NCIC Clinical Trials Group
Network
Eligibility
18 Years to 79 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2009
U.S. locations
16
States / cities
Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2020 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
FOLFOX regimen, fluorouracil, isolated perfusion, leucovorin calcium, melphalan, oxaliplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced May 21, 2026, 5:33 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer, NSCLC, Recurrent, Non-Small Cell Squamous Lung Cancer, Pancreas Cancer, Pancreatic Neoplasm, Colorectal Adenocarcinoma, CRC, Colon Cancer, Rectal Cancer, Cancer, Ovarian Cancer, Ovarian Neoplasms, Mesothelioma, Mesothelioma, Malignant, Ovary Cancer, Lung Cancer, MESOM
Interventions
A2B694, A2B543, xT CDx with HLA-LOH Assay
Biological · Diagnostic Test
Lead sponsor
A2 Biotherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
12
States / cities
Gilbert, Arizona • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Anal Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer, Pancreatic Cancer
Interventions
Recombinant Interleukin-12
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2012 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
gamma-secretase/Notch signalling pathway inhibitor RO4929097, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Colorectal Cancer, Pancreatic Cancer
Interventions
filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody MN-14, yttrium Y 90 monoclonal antibody MN-14
Biological · Procedure · Radiation
Lead sponsor
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
3
States / cities
Belleville, New Jersey • Paterson, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 21, 2011 · Synced May 21, 2026, 5:33 PM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
bevacizumab, capecitabine, oxaliplatin, conventional surgery, neoadjuvant therapy, radiofrequency ablation
Biological · Drug · Procedure
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Colorectal Cancer
Interventions
irinotecan hydrochloride, surgical procedure
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
dasatinib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 18, 2014 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
fluorouracil, leucovorin calcium, vorinostat, pharmacological study
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2014 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Rectal Mucinous Adenocarcinoma, Rectal Signet Ring Cell Adenocarcinoma, Recurrent Rectal Carcinoma, Stage IIA Rectal Cancer AJCC v7, Stage IIB Rectal Cancer AJCC v7, Stage IIC Rectal Cancer AJCC v7, Stage IIIA Rectal Cancer AJCC v7, Stage IIIB Rectal Cancer AJCC v7, Stage IIIC Rectal Cancer AJCC v7, Stage IVA Rectal Cancer AJCC v7, Stage IVB Rectal Cancer AJCC v7
Interventions
Radiotherapy, Fluorouracil, Leucovorin Calcium, Oxaliplatin, Irinotecan
Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 3, 2018 · Synced May 21, 2026, 5:33 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Melanoma, Solid Tumor, CRAF Gene Amplification, RAF1 Gene Amplification, BRAF Gene Fusion, BRAF Fusion, CRAF Gene Fusion, CRAF Fusion, RAF1 Gene Fusion, RAF1 Fusion, Thyroid Cancer, Papillary, Spitzoid Melanoma, Pilocytic Astrocytoma, Pilocytic Astrocytoma, Adult, Non Small Cell Lung Cancer, Non-Small Cell Adenocarcinoma, Colorectal Cancer, Pancreatic Acinar Carcinoma, Spitzoid Malignant Melanoma, Bladder Cancer, Bladder Urothelial Carcinoma, MAP Kinase Family Gene Mutation, RAF Mutation
Interventions
Tovorafenib
Drug
Lead sponsor
Day One Biopharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Los Angeles, California • Newport Beach, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Mucinous Adenocarcinoma of the Rectum, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Rectum, Rectal Adenocarcinoma, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer
Interventions
intensity-modulated radiation therapy, fluorouracil, oxaliplatin, leucovorin calcium, therapeutic conventional surgery
Radiation · Drug · Procedure
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced May 21, 2026, 5:33 PM EDT
Terminated Phase 1 Interventional Results available
View directory record Official record
Conditions
Colorectal Cancer
Interventions
monoclonal antibody hu3S193
Biological
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced May 21, 2026, 5:33 PM EDT
Terminated Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
fluorouracil, sodium phenylbutyrate, indomethacin, recombinant interferon gamma
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced May 21, 2026, 5:33 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Recurrent Colorectal Carcinoma, Stage III Colon Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Colon Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Colon Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Colon Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Stage IVA Colon Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Rectal Cancer AJCC v8, Stage IVB Colon Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Rectal Cancer AJCC v8, Stage IVC Colon Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Stage IVC Rectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Colorectal Carcinoma, Unresectable Rectal Adenocarcinoma
Interventions
Abemaciclib, Cetuximab, ERK1/2 Inhibitor LY3214996
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Cancer
Interventions
isolated perfusion, melphalan
Drug
Lead sponsor
Delcath Systems Inc.
Industry
Eligibility
16 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2013 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Colorectal Cancer
Interventions
gefitinib
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
16
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Colon Adenocarcinoma, Rectal Adenocarcinoma, Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
Capecitabine, Laboratory Biomarker Analysis, Nintedanib, Pharmacological Study
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
2
States / cities
Duarte, California • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced May 21, 2026, 5:33 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer, Malignant Pleural Mesothelioma, Advanced, Malignant Peritoneal Mesothelioma, Advanced, Pancreatic Adenocarcinoma Advanced or Metastatic, Lung Adenocarcinoma Metastatic, Cholangiocarcinoma Advanced, Cholangiocarcinoma Non-resectable, Mesothelin-expressing Advanced Cancers, Mesothelin-positive Advanced Malignant Solid Tumors, Colorectal Cancer
Interventions
CT-95
Drug
Lead sponsor
Context Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Denver, Colorado • Chicago, Illinois • Grand Rapids, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced May 21, 2026, 5:33 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Colorectal Cancer
Interventions
capecitabine, 5-fluorouracil, Surgical Resection, Radiation therapy
Drug · Procedure · Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced May 21, 2026, 5:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Healthy Subject, Localized Transitional Cell Cancer of the Renal Pelvis and Ureter, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Psychosocial Effects of Cancer and Its Treatment, Recurrent Bladder Cancer, Recurrent Cervical Cancer, Recurrent Colon Cancer, Recurrent Gastric Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Recurrent Renal Cell Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Recurrent Uterine Sarcoma, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter, Stage II Bladder Cancer, Stage II Renal Cell Cancer, Stage II Urethral Cancer, Stage IIA Cervical Cancer, Stage IIA Colon Cancer, Stage IIA Gastric Cancer, Stage IIA Ovarian Epithelial Cancer, Stage IIA Ovarian Germ Cell Tumor, Stage IIA Pancreatic Cancer, Stage IIA Rectal Cancer, Stage IIA Uterine Sarcoma, Stage IIB Cervical Cancer, Stage IIB Colon Cancer, Stage IIB Gastric Cancer, Stage IIB Ovarian Epithelial Cancer, Stage IIB Ovarian Germ Cell Tumor, Stage IIB Pancreatic Cancer, Stage IIB Rectal Cancer, Stage IIB Uterine Sarcoma, Stage IIC Colon Cancer, Stage IIC Ovarian Epithelial Cancer, Stage IIC Ovarian Germ Cell Tumor, Stage IIC Rectal Cancer, Stage III Bladder Cancer, Stage III Pancreatic Cancer, Stage III Renal Cell Cancer, Stage III Urethral Cancer, Stage IIIA Cervical Cancer, Stage IIIA Colon Cancer, Stage IIIA Gastric Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIA Ovarian Germ Cell Tumor, Stage IIIA Rectal Cancer, Stage IIIA Uterine Sarcoma, Stage IIIB Cervical Cancer, Stage IIIB Colon Cancer, Stage IIIB Gastric Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIB Ovarian Germ Cell Tumor, Stage IIIB Rectal Cancer, Stage IIIB Uterine Sarcoma, Stage IIIC Colon Cancer, Stage IIIC Gastric Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IIIC Ovarian Germ Cell Tumor, Stage IIIC Rectal Cancer, Stage IIIC Uterine Sarcoma, Stage IV Bladder Cancer, Stage IV Gastric Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Pancreatic Cancer, Stage IV Renal Cell Cancer, Stage IV Urethral Cancer, Stage IVA Cervical Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVA Uterine Sarcoma, Stage IVB Cervical Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer, Stage IVB Uterine Sarcoma, Ureter Cancer, Stage IIA Lung Carcinoma, Stage IIB Lung Carcinoma, Stage IIIA Lung Carcinoma, Stage IIIB Lung Carcinoma
Interventions
educational intervention, telephone-based intervention, quality-of-life assessment, questionnaire administration
Other · Behavioral · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced May 21, 2026, 5:33 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Liver Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Skin Neoplasm, Metastatic Malignant Solid Neoplasm, Resectable Lung Non-Small Cell Carcinoma, Early Stage Lung Non-Small Cell Carcinoma, Resectable Malignant Solid Neoplasm, Resectable Triple-Negative Breast Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Recurrent Cervical Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Malignant Skin Neoplasm, Recurrent Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Tissue Collection
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced May 21, 2026, 5:33 PM EDT